Xu JJ, Ni CX. Letter to the Editor: Beyond cyst size - a time-risk-state framework for dynamic surveillance de-escalation of branch duct intraductal papillary mucinous neoplasms. World J Clin Oncol 2026; 17(7): 123540 [DOI: 10.5306/wjco.123540]
Corresponding Author of This Article
Jia-Ju Xu, MD, Department of Medical Oncology, Tai’an City Central Hospital, No. 29 Longtan Road, Tai’an 271000, Shandong Province, China. jiajuxu1101@163.com
Research Domain of This Article
Oncology
Article-Type of This Article
letter
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Share the Article
Xu JJ, Ni CX. Letter to the Editor: Beyond cyst size - a time-risk-state framework for dynamic surveillance de-escalation of branch duct intraductal papillary mucinous neoplasms. World J Clin Oncol 2026; 17(7): 123540 [DOI: 10.5306/wjco.123540]
World J Clin Oncol. Jul 24, 2026; 17(7): 123540 Published online Jul 24, 2026. doi: 10.5306/wjco.123540
Letter to the Editor: Beyond cyst size - a time-risk-state framework for dynamic surveillance de-escalation of branch duct intraductal papillary mucinous neoplasms
Jia-Ju Xu, Chun-Xiao Ni
Jia-Ju Xu, Department of Medical Oncology, Tai’an City Central Hospital, Tai’an 271000, Shandong Province, China
Chun-Xiao Ni, Department of Minimally Invasive Oncology, Tai’an City Central Hospital, Tai’an 271000, Shandong Province, China
Co-first authors: Jia-Ju Xu and Chun-Xiao Ni.
Author contributions: Xu JJ was responsible for the conceptualization, methodology, and supervision; Xu JJ and Ni CX performed the writing, editing, and literature review; Both authors approved the final version. Xu JJ and Ni CX contributed equally to this work as co-first authors.
AI contribution statement: DeepSeek was used solely for linguistic refinement and formatting assistance. No AI tool was involved in the generation of research data, interpretation of results, or formulation of conclusions. All AI-generated outputs were critically reviewed and revised by the authors.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Corresponding author: Jia-Ju Xu, MD, Department of Medical Oncology, Tai’an City Central Hospital, No. 29 Longtan Road, Tai’an 271000, Shandong Province, China. jiajuxu1101@163.com
Received: May 25, 2026 Revised: July 10, 2026 Accepted: July 15, 2026 Published online: July 24, 2026 Processing time: 64 Days and 17.4 Hours
Abstract
For incidentally detected branch duct intraductal papillary mucinous neoplasms, the long-term surveillance strategy faces a difficult trade-off among clinical benefit, healthcare burden, and patient quality of life. Using a 17-year real-world cohort, the article by Hopley et al published in the World Journal of Gastroenterology showed that most clinically relevant lesion transformations and surgical interventions occur within the first 2 years; thereafter, the incremental benefit declines sharply. In this letter, we propose a framework for dynamic surveillance de-escalation. It has three dimensions: Time, risk, and patient status. The key innovation is the explicit incorporation of the patient’s overall health trajectory together with cyst biological behavior as decision drivers. At the 2-year landmark, patients with a cyst size < 30 mm and a serum carbohydrate antigen 19-9 level < 43 kU/L should transition from intensive tumor screening to chronic disease-style follow-up aimed at preventing overtreatment.
Core Tip: This letter proposes a three-dimensional dynamic surveillance de-escalation framework for branch duct intraductal papillary mucinous neoplasms. After 2 years of stability, patients with a cyst size < 30 mm and a serum carbohydrate antigen 19-9 level < 43 kU/L can safely transition from intensive tumor screening to chronic disease-style follow-up aimed at preventing overtreatment.
